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1. INTRODUCTION {#dom12757-sec-0001}
===============

Despite advances in insulin therapy, hypoglycaemia remains a significant concern and limits optimization of insulin dosing to achieve glycaemic targets.[1](#dom12757-bib-0001){ref-type="ref"} Hypoglycaemia is associated with increased morbidity and cardiovascular risk.[1](#dom12757-bib-0001){ref-type="ref"} Patients/caregivers may be fearful of nocturnal hypoglycaemia, which may affect sleep and well‐being.[2](#dom12757-bib-0002){ref-type="ref"}

Basal insulin peglispro (BIL) is PEGylated insulin lispro and has a flat pharmacokinetic profile with a 2‐3 day half‐life.[3](#dom12757-bib-0003){ref-type="ref"} BIL has an hepato‐preferential action versus glargine as a result of a reduced peripheral action rather than an enhanced effect on the liver [4](#dom12757-bib-0004){ref-type="ref"} ^(Fig\ 2)^. The primary objective of the BIL phase III studies was to demonstrate the non‐inferiority of glycated haemoglobin (HbA1c) for BIL versus glargine. The three double‐blind studies were also powered for the key secondary objective of superiority of BIL versus glargine for reduction in nocturnal hypoglycaemia rate.

In five phase III IMAGINE trials, BIL treatment met the primary objective of non‐inferiority to glargine for HbA1c.[5](#dom12757-bib-0005){ref-type="ref"}, [6](#dom12757-bib-0006){ref-type="ref"}, [7](#dom12757-bib-0007){ref-type="ref"}, [8](#dom12757-bib-0008){ref-type="ref"}, [9](#dom12757-bib-0009){ref-type="ref"} The five IMAGINE trials also resulted in 0.2--0.5% greater HbA1c reduction versus glargine over 26, 52 and 78 weeks in patients with type 1 diabetes (T1D) and those with type 2 diabetes (T2D), meeting the key secondary objective of statistical superiority (with multiplicity adjustment), with higher basal insulin doses.[5](#dom12757-bib-0005){ref-type="ref"}, [6](#dom12757-bib-0006){ref-type="ref"}, [7](#dom12757-bib-0007){ref-type="ref"}, [8](#dom12757-bib-0008){ref-type="ref"}, [9](#dom12757-bib-0009){ref-type="ref"}

The present report summarizes prespecified pooled hypoglycaemia analyses from the IMAGINE studies with a glargine comparator.

2. METHODS {#dom12757-sec-0002}
==========

Table [1](#dom12757-tbl-0001){ref-type="table-wrap"} provides an overview of the five phase III IMAGINE studies of BIL versus glargine that were included in the prespecified pooled analyses of: patients with T2D receiving basal insulin only; patients with T2D receiving basal‐bolus insulin; and patients with T1D receiving basal‐bolus insulin. Entry criteria, study design, dosing algorithms and results, including individual study glycaemic/hypoglycaemia data, have been previously reported.[5](#dom12757-bib-0005){ref-type="ref"}, [6](#dom12757-bib-0006){ref-type="ref"}, [7](#dom12757-bib-0007){ref-type="ref"}, [8](#dom12757-bib-0008){ref-type="ref"}, [9](#dom12757-bib-0009){ref-type="ref"} All were treat‐to‐target trials with the same basal‐bolus insulin‐dosing algorithms applied to both treatments and with a fasting/pre‐meal self‐monitored blood glucose (SMBG) target of 5.6 mmol/L.

###### 

Overview of IMAGINE studies, patient clinical characteristics, glycated haemoglobin and insulin dose

  Overview of IMAGINE studies                                                                                                                                         
  ----------------------------- --------------- --------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  Study                               IMAGINE 2       IMAGINE 5   IMAGINE 4[1](#dom12757-note-0003){ref-type="fn"}   IMAGINE 1[1](#dom12757-note-0003){ref-type="fn"}   IMAGINE 3[1](#dom12757-note-0003){ref-type="fn"}
  Prior treatment                 Insulin‐naïve   Basal insulin                               ≥1 insulin injection                                        Basal‐bolus                                        Basal‐bolus
  OAMs during study                          ≤3              ≤3                                     Metformin only                                                N/A                                                N/A
  Blinding                         Double‐blind      Open‐label                                       Double‐blind                                         Open‐label                                       Double‐blind
  HbA1c inclusion criteria, %              7‐11              ≤9                                           ≥7, \<12                                               \<12                                               \<12
  Study duration, weeks                   52‐78              52                                                 26                                                 78                                                 52

  Summary of patient clinical characteristics and HbA1c                                                                                                                                                                                                                                  
  ----------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------ ------------- -------------
  Age[2](#dom12757-note-0004){ref-type="fn"}, years                 59.6 ± 9.9                                                    59.5 ± 9.6                                                    57.8 ± 9.2                                                    57.4 ± 9.2   41.4 ± 13.5   41.0 ± 13.4
  Men, n (%)                                                        401 (57.8)                                                    725 (55.3)                                                    404 (59.6)                                                    376 (54.4)   368 (60.3)    535 (55.8)
  BMI[2](#dom12757-note-0004){ref-type="fn"}, kg/m^2^ (baseline)    32.0 ± 5.1                                                    32.2 ± 5.2                                                    33.0 ± 5.6                                                    33.3 ± 5.7   26.2 ± 4.0    26.2 ± 3.9
  Diabetes duration[2](#dom12757-note-0004){ref-type="fn"}, years   11.3 ± 6.7                                                    11.1 ± 6.4                                                    14.2 ± 7.8                                                    14.1 ± 7.0   19.0 ± 12.5   18.9 ± 12.1
  HbA1c[5](#dom12757-note-0007){ref-type="fn"}, %                                                                                                                                                                                                                                        
  Baseline                                                          8.2 ± 0.04                                                    8.2 ± 0.03                                                    8.5 ± 0.04                                                    8.4 ± 0.04   7.8 ± 0.05    7.8 ± 0.04
  Endpoint[3](#dom12757-note-0005){ref-type="fn"}                   7.2 ± 0.04                                                    6.9 ± 0.03                                                    7.0 ± 0.04                                                    6.8 ± 0.04   7.6 ± 0.03    7.4 ± 0.03
  LS mean difference (95% CI)                                       −0.33 (−0.42, −0.23)[4](#dom12757-note-0006){ref-type="fn"}   −0.21 (−0.31, −0.11)[4](#dom12757-note-0006){ref-type="fn"}   −0.23 (−0.31, −0.14)[4](#dom12757-note-0006){ref-type="fn"}                              

  **Insulin dose at study endpoint**                                                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------- ------------ --------------------------------------------------- ------------ --------------------------------------------------- ------------- --------------------------------------------------- ------------ ---------------------------------------------------
  Basal insulin dose[3](#dom12757-note-0005){ref-type="fn"}, [5](#dom12757-note-0007){ref-type="fn"}, U   39.0 ± 1.0   42.7 ± 0.8[4](#dom12757-note-0006){ref-type="fn"}   47.0 ± 1.6   54.5 ± 1.2[4](#dom12757-note-0006){ref-type="fn"}   60.3 ± 1.2    67.6 ± 1.2[4](#dom12757-note-0006){ref-type="fn"}   28.3 ± 0.6   35.1 ± 0.5[4](#dom12757-note-0006){ref-type="fn"}
  Bolus insulin dose[3](#dom12757-note-0005){ref-type="fn"}, [5](#dom12757-note-0007){ref-type="fn"}, U                                                                                                                                     62.8 ± 1.7    61.1 ± 1.7                                          35.8 ± 0.7   26.2 ± 0.6[4](#dom12757-note-0006){ref-type="fn"}
  Total insulin dose[3](#dom12757-note-0005){ref-type="fn"}, [5](#dom12757-note-0007){ref-type="fn"}, U                                                                                                                                     121.0 ± 2.6   125.9 ± 2.6                                         62.8 ± 1.0   59.5 ± 0.9[4](#dom12757-note-0006){ref-type="fn"}

GL, insulin glargine; LS, least squares; OAM, oral antihyperglycaemic medication; s.d., standard deviation; s.e., standard error.

Electronic diaries used.

Mean ± s.d.

52 weeks for T2D basal only; 26 weeks for T2D basal‐bolus; 52 weeks for T1D.

p \< .05 for between treatment group comparison.

LS mean ± s.e.

Hypoglycaemia was defined as SMBG ≤3.9 mmol/L or hypoglycaemia signs/symptoms. Nocturnal hypoglycaemia was an event between bedtime and waking for T2D basal‐only studies (IMAGINE 2 and 5). For studies using electronic diaries (IMAGINE 1, 3 and 4) with direct transfer of time/date stamped SMBG values,[10](#dom12757-bib-0010){ref-type="ref"} nocturnal hypoglycaemia was defined both as between bedtime and waking and between 22:00 and 10:00 hours. Hypoglycaemia at other times was daytime hypoglycaemia. Severe hypoglycaemia was investigator‐determined and defined as episodes accompanied by neurological impairment requiring medical assistance to administer carbohydrates, glucagon or other resuscitative actions.

Study durations ranged from 26 to 78 weeks (Table [1](#dom12757-tbl-0001){ref-type="table-wrap"}). For the pooled analyses of patients with T2D on basal insulin only (IMAGINE 2 and 5) and patients with T1D (IMAGINE 1 and 3), 52‐week data were included, as this was a consistent time point. IMAGINE 4, the only T2D basal‐bolus trial, was a 26‐week study.

Blinded continuous glucose monitoring (CGM) was performed in patient subsets in the three double‐blind studies (IMAGINE 2, 3 and 4) to assess duration (min) with glucose values ≤3.9 mmol/L from 00:00 to 06:00 hours and over 24 hours and duration of individual hypoglycaemic episodes. The Medtronic CGMS iPro Continuous Glucose Recorder (IMAGINE 3) or the iPro2 Professional CGM (IMAGINE 2 and 4) were used over 3 or 6 days, respectively. CGM data were centrally collected (Phase V Technologies, Wellesley, Massachusetts) at baseline/prespecified time points during treatment. The 52‐week data are presented for IMAGINE 2 and 3 and 26‐week data for IMAGINE 4 (Table S1, Appendix S1).

Analyses (SAS 9.1, Cary, North Carolina) were conducted on the modified intention‐to‐treat population of all randomized patients who received ≥1 study insulin dose. All tests were conducted at a two‐sided α value = 0.05 and 95% confidence intervals (CIs) were calculated. Pooling of studies for HbA1c was prespecified. All continuous variables were analysed using mixed linear models with repeated measurements. Total/nocturnal hypoglycaemia frequencies were analysed using negative binomial regression and a model‐based rate for each treatment was estimated.[11](#dom12757-bib-0011){ref-type="ref"} The rate of severe hypoglycaemia was analysed using an empirical method; hypoglycaemia incidence was assessed using a logistic regression model or Cochran--Mantel--Haenszel test (if \<10 patients with events). Analysis of variance was used for continuous variables collected at baseline.

3. RESULTS {#dom12757-sec-0003}
==========

A total of 4927 patients randomized to bedtime BIL (n = 2949) or glargine (n = 1978) were included. Baseline characteristics were similar between groups (Table [1](#dom12757-tbl-0001){ref-type="table-wrap"}). Across the studies, 49--72% of patients with T2D and 64--71% of patients with T1D were previously treated with glargine.

The pooled analyses were consistent with the individual study results, with a 0.21--0.33% greater reduction in HbA1c with BIL versus glargine (Table [1](#dom12757-tbl-0001){ref-type="table-wrap"}).

Basal insulin doses were 10--24% higher with BIL versus glargine across phase III studies (Table [1](#dom12757-tbl-0001){ref-type="table-wrap"}).[5](#dom12757-bib-0005){ref-type="ref"}, [6](#dom12757-bib-0006){ref-type="ref"}, [7](#dom12757-bib-0007){ref-type="ref"}, [8](#dom12757-bib-0008){ref-type="ref"}, [9](#dom12757-bib-0009){ref-type="ref"} Bolus insulin doses were 27% lower with BIL versus glargine in T1D (Table [1](#dom12757-tbl-0001){ref-type="table-wrap"}), but not statistically significantly different in patients with T2D receiving basal‐bolus insulin (Table [1](#dom12757-tbl-0001){ref-type="table-wrap"}).[6](#dom12757-bib-0006){ref-type="ref"}

Nocturnal hypoglycaemia rates were reduced by 36% in patients with T2D on basal insulin only, 45% in patients with T2D on basal‐bolus insulin, and 43% in patients with T1D with BIL versus glargine (Figure [1](#dom12757-fig-0001){ref-type="fig"}A). Nocturnal hypoglycaemia incidence was statistically significantly lower with BIL versus glargine in all patient populations (Figure [1](#dom12757-fig-0001){ref-type="fig"}B). The nocturnal hypoglycaemia rate and incidence sensitivity analyses were consistent with the primary results including: prespecified analyses of the alternative nocturnal hypoglycaemia definition for basal only and basal‐bolus e‐diary studies and *post hoc* analyses including events between 00:01 and 05:59 hours (Figure S1, Appendix S1).

![Nocturnal, total, daytime and severe hypoglycaemia. A, Nocturnal hypoglycaemia rate per patient‐year ± standard error (s.e.). B, Nocturnal hypoglycaemia incidence. C, Total hypoglycaemia rate per patient‐year ± s.e. D, Total hypoglycaemia incidence. E, Daytime hypoglycaemia rate per patient‐year ± s.e. F, Severe hypoglycaemia rate per 100 patient‐years. Values are aggregated rate**,** calculated using the total number of severe hypoglycaemia episodes divided by the cumulative days on treatment from all patients within that treatment, then times 36 525 days (for rate per 100 years). G, Severe hypoglycaemia incidence. Weeks of study data included: T2D basal only (0‐52 weeks), T2D basal‐bolus (0‐26 weeks), T1D (0‐52 weeks). B, basal only; BB, basal‐bolus; GL, insulin glargine; RR, relative rate. \*p \< .05 for between‐treatment‐group comparisons.](DOM-18-1093-g001){#dom12757-fig-0001}

The total hypoglycaemia rate was not significantly different in patients with T2D on basal insulin only, there was a 10% higher trend in patients with T2D on basal‐bolus insulin (p = .053), and the rate was 15% higher in patients with T1D (p \< .001) with BIL versus glargine (Figure [1](#dom12757-fig-0001){ref-type="fig"}C). The total hypoglycaemia incidence was not different between treatments in any population (Figure [1](#dom12757-fig-0001){ref-type="fig"}D). In patients with T1D or T2D on basal‐bolus insulin, daytime hypoglycaemia was significantly higher with BIL versus glargine (Figure [1](#dom12757-fig-0001){ref-type="fig"}E) from 0 to 52 and 0 to 26 weeks, respectively. In T1D patients, during the maintenance period of 26‐52 weeks, the total hypoglycaemia relative rate (BIL/glargine) was 1.07 (95% CI 1.00, 1.14; p = .062; Figure S2, Appendix S1).

There were no significant differences in the rate or incidence of severe hypoglycaemia between treatments in all three patient populations (Figure [1](#dom12757-fig-0001){ref-type="fig"}F and G).

In the three double‐blind studies, CGM was performed in patient subsets (BIL, n = 313, glargine, n = 215). In patients with T1D or T2D, there were no significant treatment differences in duration with glucose level ≤3.9 mmol/L (00:00--06:00 hours or over 24 hours) or in the average duration of individual hypoglycaemic episodes with BIL versus glargine (Table S1, Appendix S1).

4. DISCUSSION {#dom12757-sec-0004}
=============

The present analyses provide a summary of prespecified and pooled hypoglycaemia analyses from the five IMAGINE studies with glargine comparator. BIL treatment resulted in a 36--45% reduction in nocturnal hypoglycaemia rate versus glargine, despite greater reduction in HbA1c and higher basal insulin dosing. There was a 15% increase in total hypoglycaemia in T1D with an associated increase in daytime hypoglycaemia with basal‐bolus therapy in T1D and T2D. CGM in patient subsets showed no evidence of prolongation or shortening of hypoglycaemic episodes with BIL versus glargine. There were no significant differences in severe hypoglycaemia among the three populations. Nocturnal hypoglycaemia was also reduced with morning dosing of BIL versus glargine in T1D and T2D phase II studies[12](#dom12757-bib-0012){ref-type="ref"}, [13](#dom12757-bib-0013){ref-type="ref"} and nocturnal/total hypoglycaemia were similar with bedtime versus 8‐40‐hours variable‐time dosing of BIL in a T1D phase III study.[14](#dom12757-bib-0014){ref-type="ref"}

The significant reduction in nocturnal hypoglycaemia was achieved simultaneously with greater improvements in HbA1c with BIL versus glargine. In contrast, significant reductions in nocturnal hypoglycaemia rates were reported in clinical studies of insulin degludec[15](#dom12757-bib-0015){ref-type="ref"} and glargine U‐300[16](#dom12757-bib-0016){ref-type="ref"} versus glargine U‐100, but with non‐inferiority of HbA1c. This may reflect the hepato‐preferential action of BIL as well as longer duration of action, lower peak‐to‐trough ratio, and reduced glucose variability versus glargine U‐100 seen across the BIL phase III trials.[5](#dom12757-bib-0005){ref-type="ref"}, [6](#dom12757-bib-0006){ref-type="ref"}, [7](#dom12757-bib-0007){ref-type="ref"}, [8](#dom12757-bib-0008){ref-type="ref"}, [9](#dom12757-bib-0009){ref-type="ref"} A study in the conscious dog has shown that peripheral insulin delivery increased hypoglycaemia risk versus portal vein insulin delivery, suggesting that hepato‐preferential insulin analogues may be associated with a lower risk of hypoglycaemia.[17](#dom12757-bib-0017){ref-type="ref"} Glucose variability has also been independently associated with the risk of hypoglycaemia.[18](#dom12757-bib-0018){ref-type="ref"}, [19](#dom12757-bib-0019){ref-type="ref"}

Increased daytime hypoglycaemia with BIL versus glargine in basal‐bolus therapy may also reflect the hepato‐preferential action and longer duration of action of BIL. In T1D, the adjustment of basal‐bolus dosing occurred gradually during the titration period and resulted in significantly reduced bolus insulin requirements with BIL compared with glargine. During the maintenance period of 26‐52 weeks and after basal‐bolus dose adjustment and stabilization, total hypoglycaemia decreased in T1D and was not significantly different between groups (Figure S2, Appendix S1).

The strengths of the present pooled analyses of five BIL phase III studies include the double‐blind design of three trials, which were also powered to detect differences in nocturnal hypoglycaemia, the large sample size of \>4900 patients, as well as the global nature of the studies. The use of an e‐diary in three basal‐bolus studies[10](#dom12757-bib-0010){ref-type="ref"} allowed wireless, direct capture of SMBG values and hypoglycaemic events. Treat‐to‐target fasting SMBG levels were not significantly different in the BIL and glargine groups. Limitations include the ability to translate the findings outside of a clinical trial setting and exclusion of patients with T1D with \>1 and patients with T2D with ≥1 severe hypoglycaemic episode within 6 months of screening. In addition, it is unknown from these studies if other basal‐bolus insulin‐dosing algorithms, including algorithms different from those used with conventional basal insulins, could more rapidly optimize bolus insulin dosing with BIL.

In conclusion, across five phase III trials, BIL treatment resulted in greater HbA1c reduction with less nocturnal hypoglycaemia in all patient populations compared with glargine despite higher basal insulin doses. Basal‐bolus treatment with BIL versus glargine resulted in higher daytime hypoglycaemia in T1D and T2D, with an associated increase in total hypoglycaemia in patients with T1D.

Supporting information
======================

###### 

**Table S1.** Duration of hypoglycemia as assessed by continuous glucose monitoring (CGM) in three double‐blind IMAGINE studies.

**Figure S1.** Sensitivity analyses for nocturnal hypoglycemia between 00:00 and 05:59 hours. A, Nocturnal hypoglycemia rate per patient year ± SE. B, Nocturnal hypoglycemia incidence. Weeks of study data included: T2D basal only (0‐52 weeks), T2D basal‐bolus (0‐26 weeks), T1D (0‐52 weeks). Abbreviations: B, basal only; BB, basal‐bolus; BIL, basal insulin peglispro; CI, confidence interval; GL, insulin glargine; pt, patient; RR, relative rate; SE, standard error; T1D, type 1 diabetes; T2D,type 2 diabetes; yr, year. \*p \< .05 for between treatment group comparisons.

**Figure S2.** Total hypoglycemia rate in T1D. Values are rate per patient year ± SE. Abbreviations: BIL, basal insulin peglispro; GL, insulin glargine; SE, standard error; T1D, type 1 diabetes. \*p \< .05 for between treatment group comparisons.

###### 

Click here for additional data file.
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